down arrow

NeuroBo Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US64132R4048
USD
0.67
0.07 (10.83%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.590.69

52 Week

0.552.75
Valuation
Technical
Day's Volume

CASH

458.04 k

Shareholding (Mar 2025)

FII

0.00%

Held by 3 FIIs

DII

98.79%

Held by 1 DIIs

Promoter

0.00%

How big is NeuroBo Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, NeuroBo Pharmaceuticals, Inc. has a market capitalization of 13.56 million and reported net sales of 0.00 million with a net profit of -24.54 million over the last four quarters. Shareholder's funds are 7.93 million, and total assets amount to 16.26 million.

As of Jun 18, NeuroBo Pharmaceuticals, Inc. has a market capitalization of 13.56 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.00 million, while the sum of net profit for the same period is -24.54 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 7.93 million, and total assets amount to 16.26 million.

Read More

What does NeuroBo Pharmaceuticals, Inc. do?

22-Jun-2025

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative disorders, with a market cap of $13.56 million and a recent net profit of -$4 million. The company is classified as a micro-cap and has no dividend yield.

Overview:<BR>NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pharmaceuticals to treat neurodegenerative disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 13.56 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.54 <BR>Return on Equity: -570.84% <BR>Price to Book: 3.09<BR><BR>Contact Details:<BR>Address: 200 BERKELEY ST., FL 19, BOSTON MA: 02116 <BR>Tel: ['1 857 7029600', '1 917 6336086'] <BR>Fax: 1 734 2930444 <BR>Website: https://www.neurobopharma.com/

Read More

Who are in the management team of NeuroBo Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of NeuroBo Pharmaceuticals, Inc. includes Chairman Douglas Swirsky, CEO Dr. Jeong Gu Kang, and COO Akash Bakshi, along with independent directors Jason Groves, Jeong Gyun Oh, and Michael Salsbury.

As of March 2022, the management team of NeuroBo Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Douglas Swirsky, who serves as the Chairman of the Board.<BR>- Dr. Jeong Gu Kang, who holds multiple roles as President, Chief Executive Officer, Interim Chief Financial Officer, Secretary, Treasurer, and Director.<BR>- Mr. Akash Bakshi, who is the Chief Operating Officer, Senior Vice President, and Director.<BR><BR>Additionally, the board includes independent directors: Mr. Jason Groves, Mr. Jeong Gyun Oh, and Mr. Michael Salsbury.

Read More

Is NeuroBo Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of August 6, 2025, NeuroBo Pharmaceuticals, Inc. shows a mildly bearish trend with mixed signals from technical indicators, having declined 73.02% over the past year and 99.94% over five years compared to the S&P 500's gains.

As of 6 August 2025, the technical trend for NeuroBo Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish outlook, while the weekly MACD and KST suggest a mildly bullish sentiment. The monthly RSI is bullish, but the Bollinger Bands show a mixed signal with a bullish weekly and mildly bearish monthly trend. <BR><BR>In terms of performance, the stock has seen a significant decline over the longer term, with a 1Y return of -73.02% compared to the S&P 500's 17.14%, and a staggering -99.94% over 5Y against the S&P 500's 96.61%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 17 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.82

stock-summary
Return on Equity

-199.90%

stock-summary
Price to Book

1.74

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.67%
0%
-0.67%
6 Months
-1.01%
0%
-1.01%
1 Year
-74.12%
0%
-74.12%
2 Years
-81.52%
0%
-81.52%
3 Years
-57.64%
0%
-57.64%
4 Years
-99.8%
0%
-99.8%
5 Years
-87.71%
0%
-87.71%

NeuroBo Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is NeuroBo Pharmaceuticals, Inc. technically bullish or bearish?

As of 6 August 2025, the technical trend for NeuroBo Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish outlook, while the weekly MACD and KST suggest a mildly bullish sentiment. The monthly RSI is bullish, but the Bollinger Bands show a mixed signal with a bullish weekly and mildly bearish monthly trend. In terms of performance, the stock has seen a significant decline over the longer term, with a 1Y return of -73.02% compared to the S&P 500's 17.14%, and a staggering -99.94% over 5Y against the S&P 500's 96.61%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-209.69%
EBIT to Interest (avg)
-16.24
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.54
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.32%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.09
EV to EBIT
-0.09
EV to EBITDA
-0.09
EV to Capital Employed
-0.36
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-570.84%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (1.21%)

Foreign Institutions

Held by 3 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 60.40% vs -1,342.86% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.30",
          "val2": "-10.10",
          "chgp": "57.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "-0.10",
          "chgp": "300.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.00",
          "val2": "-10.10",
          "chgp": "60.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -120.80% vs 10.71% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-28.80",
          "val2": "-15.90",
          "chgp": "-81.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "3.00",
          "chgp": "-90.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-27.60",
          "val2": "-12.50",
          "chgp": "-120.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.30
-10.10
57.43%
Interest
0.00
0.00
Exceptional Items
0.20
-0.10
300.00%
Consolidate Net Profit
-4.00
-10.10
60.40%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 60.40% vs -1,342.86% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-28.80
-15.90
-81.13%
Interest
0.00
0.00
Exceptional Items
0.30
3.00
-90.00%
Consolidate Net Profit
-27.60
-12.50
-120.80%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -120.80% vs 10.71% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About NeuroBo Pharmaceuticals, Inc. stock-summary
stock-summary
NeuroBo Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. The Company is focused on developing pharmaceuticals to treat neurodegenerative disorders. The Company is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. The Company’s product candidate, NB-01, is targeting neuropathic pain with an indication in PDN. The Company also provides NB-02, which is an Alzheimer’s and tauopathies drug. Its product candidate Gemcabene is focused on developing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications such as homozygous familial hypercholesterolemia (HoFH), as well as severe hypertriglyceridemia (SHTG). It also focused on developing capsule formulation of niclosamide for coronavirus indications.
Company Coordinates stock-summary
Company Details
200 BERKELEY ST., FL 19 , BOSTON MA : 02116
stock-summary
Tel: 1 857 70296001 917 6336086
stock-summary
https://www.neurobopharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."